Dr. Dinesh Bhurani

About

Dr. Dinesh Bhurani is one of the leading Haematologist in India with special interest in Bone Marrow Transplant. He is having more than 22 years of experience in Stem cell Transplant including Allogeneic, Autologous, MUD (Matched Unrelated donor) and Haplo Stem Cell Transplant.

He received training & fellowship in Bone Marrow Transplantation from CMC Vellore and Australia.

He has done more than 1200 transplants at Rajiv Gandhi cancer institute & Research centre. He performed first haplo transplant of North India.

He is the First DM of Haematology in India from Christian Medical College, Vellore and heading the department since 2007.

PROFESSIONAL JOURNEY

Achievements

• First DM of Haematology in India
• First to perform Haplo Transplant in North India
• Credited with the maximum number of MUD Transplants in North India
• Credited with the start of multiple pioneer works in field of Haemato-oncology and organized many training  programs in this field at global level.

Awards

• The Eddie Hirst Memorial Prize awarded for Pathological Sciences at The Royal College of Pathologist, Australia
• Successful participation in CME titled "Lymphoma B-Cell " at University of Nebraska Medical Centre, American School for Continuing Medical Education

Publications

• Indian Council of Medical Research Consensus Document for the Management of Non-Hodgkin's Lymphoma (High Grade). Doval DC, Bhurani D, Nair R, Gujral S, Malhotra P, Ramanan G, Mohan R, Biswas G, Dattatreya S, Agarwal S, Pendharkar D, Julka PK, Advani SH, Dhaliwal RS, Tayal J, Sinha R, Kaur T, Rath GK. Indian J Med Paediatr Oncol. 2017 Jan-Mar;38(1):51-58. doi: 10.4103/0971-5851.203500. Review.
• Epidemiology and resistance pattern of bacterial isolates among cancer patients in a Tertiary Care Oncology Centre in North India. Batra U, Goyal P, Jain P, Upadhyay A, Sachdeva N, Agarwal M, Bhurani D, Talwar V, Gupta SK, Doval DC. Indian J Cancer. 2016 Jul-Sep;53(3):448-451. doi: 10.4103/0019-509X.200647.
• Coexistent Multiple Myeloma and SLL: A Rare Entity. Tanwar P, Jain S, Mehta A, Bhurani D, Agrawal N, Ahmed R. Indian J Hematol Blood Transfus. 2017 Mar;33(1):123-125. doi: 10.1007/s12288-016-0723-6. Epub 2016 Sep 17. No abstract available.
• Consensus in the Management of Multiple Myeloma in India at Myeloma State of the Art 2016 Conference. Yanamandra U, Khattry N, Kumar S, Raje N, Jain A, Jagannath S, Menon H, Kumar L, Varma N, Varma S, Saikia T, Malhotra P; for IMAGe Group.. Indian J Hematol Blood Transfus. 2017 Mar;33(1):15-21. doi: 10.1007/s12288-016-0773-9. Epub 2017 Jan 2. Review.
• Management of Multiple Myeloma and Usage of Bortezomib: Perspective from India and Ukraine. India and Ukraine Haemato-oncology Group., Garg A, Morgunskyy M, Belagali Y, Gupta N, Akku SP. Front Oncol. 2016 Nov 21;6:243. eCollection 2016. . Early manifestation of mild cognitive impairment in B-cell non-Hodgkin's lymphoma patients receiving CHOP and rituximab-CHOP chemotherapy. Khan MA, Garg K, Bhurani D, Agarwal NB. Naunyn Schmiedebergs Arch Pharmacol. 2016 Dec;389(12):1253-1265. Epub 2016 Aug 27. Alteration of Thyroid Function in Indian HER 2-Negative Breast Cancer Patients Undergoing Chemotherapy. Khan MA, Bhurani D, Agarwal NB. Asian Pac J Cancer Prev. 2015;16(17):7701-5.
• Epidemiology of invasive fungal diseases among patients with haematological disorders in the Asia-Pacific: a prospective observational study. Hsu LY, Lee DG, Yeh SP, Bhurani D, Khanh BQ, Low CY, Norasetthada L, Chan T, Kwong YL, Vaid AK, Alejandria I, Mendoza M, Chen CY, Johnson A, Tan TY. Clin Microbiol Infect. 2015 Jun;21(6):594.e7-11. doi: 10.1016/j.cmi.2015.02.019. Epub 2015 Mar 5. Factors influencing adherence to imatinib in Indian chronic myeloid leukemia patients: a cross-sectional study. Kapoor J, Agrawal N, Ahmed R, Sharma SK, Gupta A,  Bhurani D. Mediterr J Hematol Infect Dis. 2015 Feb 20;7(1):e2015013. doi: 10.4084/MJHID.2015.013. eCollection 2015.
• Histopathological pattern of lymphomas and clinical presentation and outcomes of diffuse large B cell lymphoma: A multicenter registry based study from India. Nimmagadda RB, Digumarti R, Nair R, Bhurani D, Raina V, Aggarwal S, Patil S, Gogoi PK, Sundaram S, Goswami C, Apte S, Chakravarthy S, Pathak A. Indian J Med Paediatr Oncol. 2013 Oct;34(4):299-304. doi: 10.4103/0971-5851.125250.
• Treatment of myelodysplastic syndrome transforming into acute myelogenous leukemia with azacytidine: a retrospective study from cancer centre in northern India. Suresh P, Sharma A,  Bhurani D. Indian J Hematol Blood Transfus. 2010 Sep;26(3):114. doi: 10.1007/s12288-010-0017-3. Epub 2010 Oct 19. No abstract available.
• Folinic acid administration following MTX as prophylaxis for GVHD in allogeneic HSCT centres in Australia and New Zealand. Bhurani D, Schifter M, Kerridge I. Bone Marrow Transplant. 2008 Oct;42(8):547-50. doi: 10.1038/bmt.2008.197. Epub 2008 Jul 14.
• The sensitivity of CD138 immunostaining of bone marrow trephine specimens for quantifying marrow involvement in MGUS and myeloma, including samples with a low percentage of plasma cells. Ng AP, Wei A, Bhurani D, Chapple P, Feleppa F, Juneja S. Haematologica. 2006 Jul;91(7):972-5.
• Successful surgical hemostasis in patients with von Willebrand disease following infusion of KoateDVI. Srivastava A, Mathews V, Bhurani D, Baidya S, Chandy M. Thromb Haemost. 2002 Mar;87(3):541-3. No abstract available.